Exploiting Ligand-binding Domain Dimerization for Development of Novel Androgen Receptor Inhibitors

Abstract excerpt

Currently, all clinically used androgen receptor (AR) antagonists target the AR ligand-binding pocket and inhibit T and dihydrotestosterone (DHT) binding. Resistance to these inhibitors in prostate cancer frequently involves AR-dependent mechanisms resulting in a retained AR dependence of the tumor. More effective or alternative AR inhibitors are therefore required to limit progression in these resistant stages....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Estrogen and related hormone effects
• Share to Mass Spectrometry Techniques and Applications
• Share to Prostate Cancer Treatment and Research